Title |
Myocardial Involvement After Hospitalization for COVID-19 Complicated by Troponin Elevation: A Prospective, Multicenter, Observational Study
|
---|---|
Published in |
Circulation, January 2023
|
DOI | 10.1161/circulationaha.122.060632 |
Pubmed ID | |
Authors |
Jessica Artico, Hunain Shiwani, James C. Moon, Miroslawa Gorecka, Gerry P. McCann, Giles Roditi, Andrew Morrow, Kenneth Mangion, Elena Lukaschuk, Mayooran Shanmuganathan, Christopher A. Miller, Amedeo Chiribiri, Sanjay K. Prasad, Robert D. Adam, Trisha Singh, Chiara Bucciarelli-Ducci, Dana Dawson, Daniel Knight, Marianna Fontana, Charlotte Manisty, Thomas A. Treibel, Eylem Levelt, Ranjit Arnold, Peter W. Macfarlane, Robin Young, Alex McConnachie, Stefan Neubauer, Stefan K. Piechnik, Rhodri H. Davies, Vanessa M. Ferreira, Marc R. Dweck, Colin Berry, John P. Greenwood |
Abstract |
Acute myocardial injury in hospitalized patients with coronavirus disease 2019 (COVID-19) has a poor prognosis. Its associations and pathogenesis are unclear. Our aim was to assess the presence, nature, and extent of myocardial damage in hospitalized patients with troponin elevation. Across 25 hospitals in the United Kingdom, 342 patients with COVID-19 and an elevated troponin level (COVID+/troponin+) were enrolled between June 2020 and March 2021 and had a magnetic resonance imaging scan within 28 days of discharge. Two prospective control groups were recruited, comprising 64 patients with COVID-19 and normal troponin levels (COVID+/troponin-) and 113 patients without COVID-19 or elevated troponin level matched by age and cardiovascular comorbidities (COVID-/comorbidity+). Regression modeling was performed to identify predictors of major adverse cardiovascular events at 12 months. Of the 519 included patients, 356 (69%) were men, with a median (interquartile range) age of 61.0 years (53.8, 68.8). The frequency of any heart abnormality, defined as left or right ventricular impairment, scar, or pericardial disease, was 2-fold greater in cases (61% [207/342]) compared with controls (36% [COVID+/troponin-] versus 31% [COVID-/comorbidity+]; P<0.001 for both). More cases than controls had ventricular impairment (17.2% versus 3.1% and 7.1%) or scar (42% versus 7% and 23%; P<0.001 for both). The myocardial injury pattern was different, with cases more likely than controls to have infarction (13% versus 2% and 7%; P<0.01) or microinfarction (9% versus 0% and 1%; P<0.001), but there was no difference in nonischemic scar (13% versus 5% and 14%; P=0.10). Using the Lake Louise magnetic resonance imaging criteria, the prevalence of probable recent myocarditis was 6.7% (23/342) in cases compared with 1.7% (2/113) in controls without COVID-19 (P=0.045). During follow-up, 4 patients died and 34 experienced a subsequent major adverse cardiovascular event (10.2%), which was similar to controls (6.1%; P=0.70). Myocardial scar, but not previous COVID-19 infection or troponin, was an independent predictor of major adverse cardiovascular events (odds ratio, 2.25 [95% CI, 1.12-4.57]; P=0.02). Compared with contemporary controls, patients with COVID-19 and elevated cardiac troponin level have more ventricular impairment and myocardial scar in early convalescence. However, the proportion with myocarditis was low and scar pathogenesis was diverse, including a newly described pattern of microinfarction. URL: https://www.isrctn.com; Unique identifier: 58667920. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 19 | 11% |
United States | 7 | 4% |
Canada | 4 | 2% |
Mexico | 2 | 1% |
Japan | 2 | 1% |
Spain | 1 | <1% |
India | 1 | <1% |
Ireland | 1 | <1% |
Belarus | 1 | <1% |
Other | 3 | 2% |
Unknown | 126 | 75% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 121 | 72% |
Scientists | 26 | 16% |
Practitioners (doctors, other healthcare professionals) | 16 | 10% |
Science communicators (journalists, bloggers, editors) | 4 | 2% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 54 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 8 | 15% |
Other | 5 | 9% |
Researcher | 4 | 7% |
Student > Bachelor | 3 | 6% |
Student > Master | 3 | 6% |
Other | 6 | 11% |
Unknown | 25 | 46% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 16 | 30% |
Biochemistry, Genetics and Molecular Biology | 4 | 7% |
Business, Management and Accounting | 2 | 4% |
Nursing and Health Professions | 2 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
Other | 3 | 6% |
Unknown | 26 | 48% |